Clinical trial · Observational
Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
The Role of Cytokines in Early Diagnosis, Assessment of Response and Prognosis of Patients With Lymphoma-associated Hemophagocytic Lymphohistiocytosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lymphoma-associated hemophagocytic lympohistiocytosis is a refractory immune disorder with high mortality. Early identification and diagnosis of lymphoma-associated HLH has become the key to improve the prognosis of lymphoma-associated HLH. Therefore, we conduct a multicenter, prospective, observational clinical study to explore the sensitivity and specificity of cytokines for the early diagnosis of lymphoma-associated HLH.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemophagocytic Lymphohistiocytoses | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytokine | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Lymphoma group
- description
- Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment.
- interventionNames
- Diagnostic Test: cytokine
- label
- Lymphoma-associated HLH group
- description
- Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment.
- interventionNames
- Diagnostic Test: cytokine
Primary outcomes (1)
- measure
- The sensitivity and specificity of cytokines to predict lymphoma-associated HLH
- timeFrame
- 1 year
- description
- The sensitivity and specificity of cytokines as a means of early diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age 40-75, gender is not limited. * Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment. * Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment. * Informed consent obtained. Exclusion Criteria: * Patients with severe active infections (viral, bacterial, fungal, or parasitic). * Patients with active autoimmune disease or a history of organ transplantation who are receiving immunosuppressive therapy. * Patients with other type of malignant tumors within 5 years, except for cured solid tumors. * Patients planned to receive immunotherapy. * Pregnant and breastfeeding females. * History of human immunodeficiency virus (HIV) infection. * Acute or chronic active hepatitis B or hepatitis C. * Patients assessed as ineligible for the study by the investigator.
References
Publications (0)
Data not yet available